Sign up for free insights newsletter
TW

Twist Bioscience Corp

TWSTUnited States

Need professional-grade analysis? Visit stockanalysis.com

$42.07
-5.38%
End of day
Market Cap

$2.58B

P/E Ratio

N/A

Employees

N/A

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino3.723.23-0.151.95
Calmar5.975.18-0.143.16
Sharpe2.151.94-0.101.14
Omega1.371.311.041.21
Martin16.4014.39-0.238.80
Ulcer8.519.2027.2316.54

Twist Bioscience Corp (TWST) Price Performance

Twist Bioscience Corp (TWST) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $42.07, down 5.38% from the previous close.

Over the past year, TWST has traded between a low of $24.16 and a high of $54.92. The stock has lost 4.9% over this period. It is currently 23.4% below its 52-week high.

Twist Bioscience Corp has a market capitalization of $2.58B.

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$391.56M
EBITDA
$-112,748,000
Profit Margin
-19.56%
EPS (TTM)
-1.27
Book Value
7.44

Technical Indicators

52 Week High
$57.88
52 Week Low
$23.30
50 Day MA
$44.05
200 Day MA
$34.36
Beta
2.29

Valuation

Trailing P/E
N/A
Forward P/E
-22.32
Price/Sales
6.59
Price/Book
5.65
Enterprise Value
$2.49B